Realizing individualized cancer treatment through patient genome sequencing

Recent Publications

Katayama, R., Gong, B., Togashi, N., Miyamoto, M., Kiga, M., Iwasaki, S., Kamai, Y., Tominaga, Y., Takeda, Y., Kagoshima, Y., Shimizu, Y., Seto, Y., Oh-hara, T., Koike, S., Nakao, N., Hanazawa, H., Watanabe, K., Yoda, S., Yanagitani, N., Hata, A. N., Shaw, A. T., Nishio, M., Fujita, N. and Isoyama, T.
The new-generation selective ROS1/NTRK Inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Nat. Commun., in press (2019)

ニュースリリース文章はこちら
Suzuki, Y., Kobayashi, K., Wakisaka, Y., Deng, D., Tanaka, S., Huang, C. J., Lei, C., Liu, H., Fujiwaki, Y., lee, S., isozaki, A., Kasai, Y., hayakawa, T., Sakuma, S., Arai, F., Koizumi, K., Tezuka, H., Inaba, M., hiraki, K., Ito, T., Hase, M., Matsusaka, S., Shiba, K., Suga, K., Nishikawa, M., Jona, M., Yatomi, Y., Yaxiaer, Y., Tanaka, Y., Sugimura, T., Nitta, N., Goda, K. and Yasuyuki, O.
Label-free chemical imaging flow cytometry by high-speed multicolor stimulated Raman scattering.
Proc. Natl. Acad. Sci. U. S. A., in press (2019)
Okada, K., Araki, M., Sakashita, T., Ma, B., Kanada, R., Yanagitani, N., Horiike, A., Koike, S., Oh-Hara, T., Watanabe, K., Tamai, K., Maemondo, M., Nishio, M., Ishikawa, T., Okuno, Y., Fujita, N. and Katayama, R.
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
EBioMedicine, 41, 105-119 (2019)
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., Takeuchi, K., Kawamoto, H., Fujita, N. and Katayama, R.
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
J. Exp. Med., 216, 982-1000 (2019)
Suenaga, M., Wakatsuki, T., Mashima, T., Ogura, M., Ichimura, T., Shinozaki, E., nakayama, I., Osumi, H., Ota, Y., Takahari, D., Chin, K., Seimiya, H. and yamaguchi, K.
A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Invest. New Drugs., in press (2019)

more